Understanding how genetics affect response to GLP1R agonists in obesity and diabetes
Official title: Pharmacogenetics of Response to GLP1R Agonists
Run by University of Maryland, Baltimore · NCT05071898 · Data updated 2026-11-12
This study is testing how genetics affect the way overweight or obese people from the Old Order Amish community respond to the diabetes medication semaglutide.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 89 Years |
| Sex | All |
| Enrollment | 600 (estimated) |
| Sponsor | University of Maryland, Baltimore Academic / other |
| Locations | 1 site (Lancaster, Pennsylvania) |
| Status | Recruiting |
| Started | April 11, 2022 |
| Main results expected | April 30, 2027 |
| Study ends | April 2028 |
| Registry record updated | July 27, 2026 |
| Trial ID | NCT05071898 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are overweight or obese individuals of Amish descent with a BMI of 27 kg/m2 or higher.
✕Probably not a fit
Patients with a history of diabetes or those who are pregnant or planning to become pregnant may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study recruits overweight or obese volunteers from the Old Order Amish population in Lancaster County, PA, to investigate the pharmacogenetic responses to the GLP1R agonist semaglutide. Participants will undergo two frequently sampled intravenous glucose tolerance tests (FSIGT) before and after a six-week treatment with semaglutide. The study aims to identify genetic variants that influence insulin secretion and glucose disappearance rates in response to the medication. Genotyping will be performed using a high-density array to comprehensively analyze DNA sequence variants.
Why it matters
Potential benefit: If successful, this study could lead to personalized treatment strategies for obesity and type 2 diabetes based on genetic profiles.
How similar studies have gone: While pharmacogenetic approaches have been explored in other contexts, this specific investigation into GLP1R agonists in the Amish population is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * BMI greater than or equal to 27 kg/m2 * Of Amish Descent Exclusion Criteria: * Woman of childbearing age who is sexually active * History of diabetes (HbA1c \> 6.5% or random glucose \>200 mg/dL) * Known allergy to semaglutide * Medical issues, which in the judgment of the research physician or PIs might increase the risk associated with participation in the study * eGFR \< 60 mL/min/1.73 sq. m. * Hematocrit \< 35% * TSH \< 0.4 o4 \> 5.5 * AST or ALT in excess of 2X the upper limit of normal * Unable to discontinue a drug, vitamin, or nutritional supplement, which in the judgment of the research physician or PIs might alter the response to semaglutide * Personal or family history of medullary carcinoma of the thyroid or multiple endocrine neoplasia, type 2
Where it's running
-
Amish Research Clinic
Lancaster, Pennsylvania, United States Recruiting
Study contacts
- Principal investigator: Amber L Beitelshees, PharmD — University of Maryland, Baltimore
- Study coordinator: Amber L Beitelshees, PharmD
- Email: abeitels@som.umaryland.edu
- Phone: (410)706-0118
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Survey to determine eligibility for cardiovascular and obesity clinical trials
This study is trying to see if people with heart issues or obesity can join new clinical trials by having them fill out a survey and undergo some health checks.
-
Exploring how macrophages affect fat metabolism in obesity
This study tests how a specific protein in immune cells affects fat processing in people with obesity compared to those who are lean.
-
Nutrition therapy program for obesity and diabetes in low-income individuals
This study tests a special meal replacement program to see if it helps low-income people with obesity and diabetes lose weight and manage their blood sugar better.
-
Ocular Changes in People Using Tirzepatide or Semaglutide
This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.
-
Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes
This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.
-
Berobenatide for knee pain in adults who are overweight or with obesity
This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.